one tidbit is that qquantrx (?) just filed to go public for 300MM, and they listed RPRX (then zona) as one of their main competitors in the field of uterine fibroid treatment, and that rprx is ahead of them in the game.
RPRX has a value of just under 111 M, with cash about 15 so the enterprise value is 90 some million.
If the investment community is placing an IPO value on quantrx of 300 that makes rprx (gotta get used to typing that now) easily worth 300 because they've got 2 drugs with 3 applications, androxal for testosterone deficiency, and proellex for both endometriosis and uterine fibroids. Each of these applications is easily worth 1B sales.
Stock is worth 40 going into time when they are anticipating results from the PIII and filing of the NDA for androxal, IMO.
One hedge fund I spoke with told me with a straight face thathe could see the company getting bought for $100 in a year......
I'll send you more DD by e-mail
--------------------------------------
silver and gold, silver and gold, E.I.E.I.O.
News 
Market Data 
Discover 
AI
